share_log

Hypera (OTCMKTS:HYPMY) Lifted to "Buy" at The Goldman Sachs Group

Hypera (OTCMKTS:HYPMY) Lifted to "Buy" at The Goldman Sachs Group

Hypera(OTCMKTS：HYPMY)在高盛被提升为“买入”
Defense World ·  2022/10/18 15:12

The Goldman Sachs Group upgraded shares of Hypera (OTCMKTS:HYPMY – Get Rating) from a neutral rating to a buy rating in a research report released on Monday morning, The Fly reports.

据The Fly报道，在周一上午发布的一份研究报告中，高盛将Hypera(场外交易代码：HYPMY-GET Rating)的股票评级从中性上调至买入。

Hypera Price Performance

Hypera性价比

Shares of HYPMY stock opened at $8.89 on Monday. Hypera has a 1 year low of $4.63 and a 1 year high of $9.17. The firm has a fifty day moving average price of $8.40 and a 200-day moving average price of $7.96.

HYPMY股票周一开盘报8.89美元。Hypera的一年低点为4.63美元，一年高位为9.17美元。该公司的50日移动均线价格为8.40美元，200日移动均线价格为7.96美元。

Get
到达
Hypera
金丝桃组
alerts:
警报：

Hypera Company Profile

Hypera公司简介

(Get Rating)

(获取评级)

Hypera SA operates as a pharmaceutical company in Brazil. It offers prescription products under the Adacne, Addera, apri, AmpliumG, please, Celestamine, Celestone, Celestone Soluspan, Cizax, deciprax, Derive C Micro, Micro Drift, Dermotil Fusid, Digedrat, diprogent, Diprosalic, Diprosone, diprospan, Emprol XR, Flow, Garasone, Halobex, Lipanon, moon, Lydian, macrodantin, MaxSulid, milgamma, Mioflex – A, nesina, Novotram, oximax, peridal, Peridal Suspension, PredSim, pressaliv, Quadriderm, Rizi, Rizi M, softalm, tacroz, tinodin, umma, and velunid brands.
Hypera SA在巴西作为一家制药公司运营。它提供的处方药有Adacne、Addera、Apri、AmpliumG、请、赛莱他明、Celstone、Celstone Soluspana、Cizax、DECPRAX、衍生CMicro、Micro Drift、Dermol Fusid、Digedrat、双丙胺、双丙沙星、双丙松、双丙松、Emprol XR、Flow、Garasone、Halobx、Lipanon、Moon、Lydian、Macrodantin、MaxSulid、MilGamma、Mioflex-A、Nesina、Novotram、oximax、peridid、Perida混悬剂、Predsim、Pressaliv、Quadriderm、Rizi、Rizi、Softalm、acrotz、tinodin、umma和velunid品牌。

Read More

阅读更多内容

  • Get a free copy of the StockNews.com research report on Hypera (HYPMY)
  • Biogen's Stock Pullback Offers a Second Chance
  • Pitch a Tent in Camping World Stock
  • Fisker is Entering a Critical Stage That Could Reward Investors
  • The Bottom Is In For JPMorgan Chase & Co.
  • The Institutions May Cap Gains In Steel Dynamics
  • 免费获取StockNews.com关于Hypera的研究报告(HYPMY)
  • Biogen的股票回调提供了第二次机会
  • 在露营世界股票中搭起帐篷
  • 菲斯克正在进入一个关键阶段，这可能会给投资者带来回报
  • 摩根大通的日子不好过了。
  • 这些机构可能会限制钢铁动力领域的收益

Receive News & Ratings for Hypera Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hypera and related companies with MarketBeat.com's FREE daily email newsletter.

接受Hypera Daily的新闻和评级-在下面输入您的电子邮件地址，通过MarketBeat.com的免费每日电子邮件时事通讯接收对Hypera和相关公司的最新新闻和分析师评级的每日简要摘要。

译文内容由第三方软件翻译。


以上内容仅用作资讯或教育之目的，不构成与富途相关的任何投资建议。富途竭力但不能保证上述全部内容的真实性、准确性和原创性。
    抢沙发